

March 6, 2018



## **BioCorRx to Exhibit at the Addiction Executives Industry Summit in Ponte Verde Beach, FL**

ANAHEIM, CA, March 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company is currently exhibiting at the Addiction Executives Industry Summit (AXIS) at the Sawgrass Marriot in Verde Beach, Florida on March 4-7th.

The C4 Recovery Foundation, Inc.'s AXIS conference is an addiction and behavioral conference and is designed for addiction executives and management from diverse organizations and functions. AXIS brings together individuals from diverse organizations to engage in a stimulating exchange of ideas on the changing healthcare environment, leadership, and business operations.

Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are happy to be exhibiting at the AXIS conference this week. This is one of the leading addiction and behavioral conferences with hundreds of attendees. We are showcasing our BioCorRx® Recovery Program, a comprehensive medication-assisted treatment (MAT) program which includes the use of naltrexone in an implantable form along with our proprietary cognitive behavioral therapy (CBT) modules and peer recovery support and tracking."

### **About BioCorRx**

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit [www.BioCorRx.com](http://www.BioCorRx.com).

### ***Safe Harbor Statement***

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations

are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.  
investors@BioCorRx.com  
714-462-4880

Investor Relations:  
Crescendo Communications, LLC  
(212) 671-1020 x304  
bicx@crescendo-ir.com



Source: BioCorRx Inc